AcelRx Tries Transparency To Reassure Investors After Zalviso ‘Complete Response’
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Trying to beat The Medicines Co. to market with a patient-administered post-surgical pain analgesic, AcelRx hopes it can refile the NDA for Zalviso by the end of 2014, based on already-filed amendments and adjustments to the delivery mechanism and instructions for use.
You may also be interested in...
AcelRx’s Pain Drug Zalviso Delayed By Delivery Device Issues
FDA’s “complete response” letter asks the company to reduce the rate of optical errors and improve the instructions for use of the patient-activated, hand-held analgesic system.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.